Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBITDA (2016 - 2025)

Historic EBITDA for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $67.4 million.

  • Haemonetics' EBITDA rose 30705.44% to $67.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $251.1 million, marking a year-over-year increase of 10964.33%. This contributed to the annual value of $221.8 million for FY2025, which is 3452.99% up from last year.
  • Per Haemonetics' latest filing, its EBITDA stood at $67.4 million for Q4 2025, which was up 30705.44% from $58.5 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' EBITDA registered a high of $71.3 million during Q1 2025, and its lowest value of -$21.2 million during Q2 2021.
  • Its 5-year average for EBITDA is $30.9 million, with a median of $30.6 million in 2024.
  • In the last 5 years, Haemonetics' EBITDA plummeted by 18142.04% in 2021 and then surged by 42727.73% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' EBITDA stood at $14.4 million in 2021, then skyrocketed by 159.36% to $37.4 million in 2022, then rose by 5.79% to $39.6 million in 2023, then plummeted by 58.15% to $16.6 million in 2024, then surged by 307.05% to $67.4 million in 2025.
  • Its EBITDA stands at $67.4 million for Q4 2025, versus $58.5 million for Q3 2025 and $53.9 million for Q2 2025.